September 11th 2024
Benjamin Besse, MD, PhD, discusses findings from the phase 3 CARMEN-LC03 trial.
April 10th 2021
Benjamin Besse, MD, discusses the results of an ad-hoc safety analysis of the phase 1/2 LIBRETTO-001 trial, which examined the use of selpercatinib in patients with RET-altered advanced medullary thyroid cancer and non–small cell lung cancer.
May 17th 2018
Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of necitumumab (Portrazza) and abemaciclib (Verzenio) in patients with stage IV non–small cell lung cancer.
April 13th 2018
Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses challenges facing the treatment of patients with stage IV non
September 20th 2017
Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with non